213
Participants
Start Date
June 21, 2018
Primary Completion Date
July 22, 2022
Study Completion Date
July 22, 2022
Oleclumab
Participants will receive IV infusion of oleclumab as stated in arm description.
Durvalumab
Participants will receive IV infusion of durvalumab as stated in arm description.
Gemcitabine
Participants will receive IV infusion of gemcitabine as stated in arm description.
Nab-paclitaxel
Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
Oxaliplatin
Participants will receive IV infusion of oxaliplatin as stated in arm description.
Folinic acid
Participants will receive IV infusion of folinic acid as stated in arm description.
5-FU
Participants will receive IV infusion of 5-FU as stated in arm description.
Research Site, St Leonards
Research Site, Blacktown
Research Site, Heidelberg
Research Site, Clayton
Research Site, Buffalo
Research Site, Philadelphia
Research Site, Charlottesville
Research Site, Durham
Research Site, Fuenlabrada
Research Site, Atlanta
Research Site, Pamplona
Research Site, Oviedo
Research Site, Fort Myers
Research Site, Nashville
Research Site, Columbus
Research Site, Cincinnati
Research Site, Ann Arbor
Research Site, Madison
Research Site, Dallas
Research Site, Houston
Research Site, Aurora
Research Site, La Jolla
Research Site, Seattle
Research Site, Boston
Research Site, Boston
Research Site, Oslo
Research Site, Barcelona
Lead Sponsor
MedImmune LLC
INDUSTRY